

Literatura ACTA MEDICINAE 17/2020 Kazuistiky

- 3 **Eskalace dávky secukinumabu u refrakterních pacientů s ankylozující spondylitidou**
prof. MUDr. Karel Pavelka, DrSc. Revmatologický ústav, Praha
- 3 **Léčba testosteronem ve formě transdermálního gelu**
MUDr. Pavel Turčan, FECSM Centrum MEDIOL, s. r. o., Ordinance sexuologie a andrologie, Olomouc
- 3 **Nebivolol v léčbě kardiovaskulárních chorob: stručná kazuistika a přehled klinických účinků**
prof. MUDr. Jiří Widimský jr., CSc. III. interní klinika, VFN a 1. LF UK, Praha
- 3 **Fixní kombinovaná terapie rosuvastatinem a ezetimibem u pacienta s diabetem 2. typu a vysokým kardiovaskulárním rizikem**
prof. MUDr. Hana Rosolová, DrSc. Centrum preventivní kardiologie, Univerzita Karlova, Lékařská fakulta v Plzni a 2. interní klinika Fakultní nemocnice Plzeň
- 3 **Včasné dosažení a dlouhodobé udržení optimálních hodnot krevního tlaku – fixní kombinační léčba v kazuistikách**
MUDr. Milan Plíva Kardiologické centrum Agel, Interní klinika – kardiologické oddělení, Nemocnice Pardubického kraje, a. s.
- 4 **Od glukocentrismu ke kardiorenální protektivě**
prof. MUDr. Jan Škrha, DrSc. III. interní klinika – klinika endokrinologie a metabolismu 1. LF UK a VFN, Praha
- 4 **Klinické zkušenosti s užitím inzulínu glargin 300 jednotek/ml v první linii u diabetes mellitus 2. typu**
MUDr. Lucie Hoskocová Interní klinika 2. LF UK a FN v Motole, Praha
- 4 **Klinické zkušenosti s fixní kombinací inzulínu glargin a lixisenatidu**
MUDr. Martina Tuháčková Interní klinika 2. LF UK a FN v Motole, Praha
- 4 **Bronchodilatační inhalační léčba u pacientů s CHOPN – aklidinium bromid v monoterapii, duální fixní kombinace aklidinium bromid / formoterol fumarát 2× denně**
MUDr. Zuzana Perná Plicní ambulance, Medicon, a. s., Praha
- 4 **Biologická léčba napříč fenotypy těžkého astmatu**
MUDr. Jana Klosová Oddělení alergologie a klinické imunologie, FN Ostrava
- 5 **Astmatický pacient u alergologa – adherence pacientů k léčbě zlepšuje léčebný efekt**
MUDr. Iva Pončáková Centrum alergologie a klinické imunologie (CAKI) Nemocnice Na Homolce, Praha
- 5 **Inhalační kortikosteroidy v léčbě průduškového astmatu – principy léčby a význam výběru**
doc. MUDr. Jaromír Bystroň, CSc. Oddělení alergologie a klinické imunologie FN Ostrava (OAKI), JB Alergo-Imuno, s. r. o., Havířov
- 5 **Atezolizumab ve druhé linii léčby nemalobuněčného plicního karcinomu**
MUDr. Markéta Černovská Pneumologická klinika 1. LF UK a Thoamyerova nemocnice, Praha
- 5 **Leiomyosarkom nadledviny léčený pazopanibem**
MUDr. Hana Švébišová Onkologická klinika, LF UP a FN Olomouc
- 5 **Ninlaro – léčebná možnost relabujícího/refrakterního mnohočetného myelomu**
MUDr. Viera Sandecká, Ph.D. Interní hematologická a onkologická klinika, FN Brno
- 6 **Léčba epizodické nenádorové bolesti kombinací tramadolu a paracetamolu**
MUDr. Marek Pieran Ambulance pro léčbu chronické bolesti při Klinice anestezie a resuscitace FN Olomouc
- 6 **Využití eribulinu v léčbě karcinomu prsu u starších žen**
MUDr. Zuzana Donátová | MUDr. Drahomíra Kordíková Onkologická klinika 1. LF UK a Thomayerova nemocnice, Praha
- 6 **Nepeglylovaný lipozomální doxorubicin v léčbě metastatického hormonálně dependentního nádoru prsu**
MUDr. Dagmar Brančíková, Ph.D. Interní hematologická a onkologická klinika FN Brno
- 6 **Lipidový komplex amfotericinu B a jeho místo vedle moderních antimykotik**
MUDr. Peter Múdry, Ph.D. Klinika dětské onkologie LF MU a FN Brno

- 6 Režim ATRA+ATO u pacientov s nízkym a stredným rizikom akútnej promyelocytovej leukémie – sledovanie hepatálnej toxicity a hyperleukocytózy**
MUDr. Iveta Oravcová, PhD. | MUDr. Eva Mikušková, PhD. | MUDr. Ľudmila Demitrovičová, PhD. | MUDr. Vanda Mikudová | MUDr. Silvia Cingelová, PhD. | MUDr. Alica Slobodová | MUDr. Jana Jankechová Oddelenie onkohematológie II, Klinika onkohematológie LF UK a NOÚ, Bratislava
doc. MUDr. Ľuboš Drgoňa, CSc. Oddelenie onkohematológie I a II, Klinika onkohematológie LFUK a NOÚ, Bratislava
- 7 Leukocytóza a diferenciálny syndrom při léčbě akutní promyelocytární leukemie pomocí oxidu arsenitého**
MUDr. Zdeněk Kořístek, Ph.D. Klinika hematooonkologie, Fakultní nemocnice Ostrava
- 7 Získaná hemofilie A: možnosti diagnostiky a léčby**
MUDr. Jaromír Gumulec | MUDr. Zdeněk Kořístek, Ph.D. | MUDr. Milan Navrátil | MUDr. David Buffa | MUDr. Katarína Hradská Klinika hematooonkologie FN Ostrava a LF Ostravské univerzity
MUDr. Lucie Recová Oddělení klinické hematologie Ústavu laboratorní diagnostiky FN Ostrava a LF Ostravské univerzity
MUDr. Radomíra Hrdličková Krevní centrum FN Ostrava a LF Ostravské univerzity
MUDr. Martin Pulcer, Ph.D. Oddělení klinické hematologie Ústavu laboratorní diagnostiky FN Ostrava a LF Ostravské univerzity
doc. MUDr. Zuzana Čermáková, Ph.D. Krevní centrum FN Ostrava a LF Ostravské univerzity
prof. MUDr. Roman Hájek, CSc. Klinika hematooonkologie FN Ostrava a LF Ostravské univerzity
- 7 Pestrost lidských povah je příčinou, proč někdy vážne komunikace mezi pacientem a lékařem**
PhDr. Mgr. Jeroným Klimeš, Ph.D. Soukromá psychologická ambulance, Praha
doc. MUDr. Zdeněk Boleloucký, CSc. Psychiatrická klinika LF MU a FN Brno
prof. MUDr. Zdeněk Adam, CSc. Interní hematologická a onkologická klinika LF MU a FN Brno
MUDr. Zuzana Adamová, Ph.D. Chirurgické oddělení, Vsetínská Nemocnice, a. s.

Eskalace dávky secukinumabu u refrakterních pacientů s ankylozující spondylitidou

prof. MUDr. Karel Pavelka, DrSc. Revmatologický ústav, Praha

- 1 Dougados, M. – Baeten, D.: Spondyloarthritis. *Lancet*, 2011, 377, s. 2127–2137.
- 2 Lie, E. – van der Heijde, D. – Uhlig, T., et al.: Effectiveness of switching between TNF inhibitors in ankylosing spondylitis: data from the NOR-DMARD register. *Ann Rheum Dis*, 2011, 70, s. 157–163.
- 3 van der Heijde, D. – Ramiro, S. – Landewé, R., et al.: 2016 update of the ASAS-EULAR management recommendations for axial spondyloarthritis. *Ann Rheum Dis*, 2017, 76, s. 978–991.
- 4 Braun, J. – van den Berg, R. – Baraliakos, X., et al.: 2010 update of the ASAS/EULAR recommendations for the management of ankylosing spondylitis. *Ann Rheum Dis*, 2011, 70, s. 896–904.
- 5 Marzo-Ortega, H. – Sieper, J. – Kivitz, A., et al.: 5-year efficacy and safety of secukinumab in patients with ankylosing spondylitis: end-of-study results from the phase 3 MEASURE 2 trial. *Rheumatology*, 2020, 2, s. e339–e346.
- 6 Smolen, J. S. – Landewé, R. B. M. – Bijlsma, J. W. J., et al.: EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2019 update. *Ann Rheum Dis*, 2020, 0, s. 1–15.
- 7 Baraliakos, X. – Braun, J. – Deodhar, A., et al.: Long-term efficacy and safety of secukinumab 150 mg in ankylosing spondylitis: 5-year results from the phase III MEASURE 1 extension study. *RMD Open*, 2019, doi:10.1136/rmdopen-2019-001005.
- 8 Pavelka, K. – Kivitz, A. J. – Dokoupilová, E., et al.: Secukinumab 150/300 mg provides sustained improvements in the signs and symptoms of active ankylosing spondylitis: 3-year results from the phase 3 MEASURE 3 study. *ACR Open Rheumatol*, 2020, 2, s. 119–127.
- 9 Smolen, J. – Schoofs, M. – Braun, J., et al.: Treating axial spondyloarthritis and peripheral spondyloarthritis to target. 2017 update of recommendations by international task force. *Ann Rheum Dis*, 2018, 77, s. 3–17.
- 10 Lukas, C. – Landewé, R. – Sieper, J., et al.: Development of an ASAS-endorsed disease activity score (ASDAS) in patients with ankylosing spondylitis. *Ann Rheum Dis*, 2009, 68, s. 18–24.

Léčba testosteronem ve formě transdermálního gelu

MUDr. Pavel Turčan, FECSM Centrum MEDIOL, s. r. o., Ordinance sexuologie a andrologie, Olomouc

- 1 Li, S.-Y. – Zhao, Y.-I. – Yang, Y.-F., et al.: Metabolic effects of testosterone replacement therapy in patients with type 2 diabetes mellitus or metabolic syndrome: a meta-analysis. *Int J Endocrinol*, 2020, 4732021. doi: 10.1155/2020/4732021.
- 2 Kim, M. – Byun, S.-S. – Hong, S. K.: Testosterone replacement therapy in men with untreated or treated prostate cancer: do we have enough evidences? *World J Mens Health*, 2020, doi: 10.5534/wjmh.190158.
- 3 Yassin, A. – AlRumaihi, K. – Alzubaidi, R., et al.: Testosterone, testosterone therapy and prostate cancer. *The Aging Male*, 2019, 22, s. 219–227.
- 4 Yeap, B. B. – Wu, F. C.: Clinical practice update on testosterone therapy for male hypogonadism: contrasting perspectives to optimize care. *Clin Endocrinol*, 2019, 90, s. 56–65.
- 5 García-Cruz, E. – Alcaraz, A.: Testosterone deficiency syndrome: Diagnosis and treatment. *Actas Urológicas Españolas*, 2020, 44, s. 294–300, DOI: 10.1016/j.acuroe.2019.10.008.
- 6 Barbonetti, A. – D'Andrea, S. – Francavilla, S.: Testosterone replacement therapy. *Andrology*, 2020, 8, s. 1551–1566, https://doi.org/10.1111/andr.12774.
- 7 Salter, C. A. – Mulhall, J. P.: Guideline of guidelines: testosterone therapy for testosterone deficiency. *BJU Int*, 2019, 124, s. 722–729.

Nebivolol v léčbě kardiovaskulárních chorob: stručná kazuistika a přehled klinických účinků

prof. MUDr. Jiří Widimský jr., CSc. III. interní klinika, VFN a 1. LF UK, Praha

- 1 Williams, B. – Mancia, G. – Spiering, W., et al.: 2018 ESC/ESH Guidelines for the management of arterial hypertension: The Task Force for the management of arterial hypertension of the European Society of Cardiology and the European Society of Hypertension. *J Hypertens*, 2018, 36, s. 1953–2041.
- 2 Widimský, J., jr. – Filipovský, J. – Ceral, J., et al.: Diagnostické a léčebné postupy u arteriální hypertenze – verze 2017. Doporučení České společnosti pro hypertenzi. *Hypertenze a kardiovaskulární prevence*, 2018, suppl., s. 1–22.
- 3 Ignarro, L. J.: Experimental evidences of nitric oxide-dependent vasodilatory activity of nebivolol, a third-generation beta-blocker. *Blood Press Suppl*, 2004, 1, s. 2–16.
- 4 Howlett, H. G.: Nebivolol: vasodilator properties and evidence for relevance in treatment of cardiovascular disease. *Canad J Cardiol*, 2014, 30, S29eS37.
- 5 Van Bortel, L. M., et al.: Pharmacological properties of nebivolol in man. *Eur J Clin Pharmacol*, 1997, 51, s. 379–384.
- 6 Cleophas, J. T.: Experimental evidences of selective antagonistic action of nebivolol on beta 1 adrenergic receptors. *J Clin Med*, 1998, 2, s. 2–8.
- 7 Routledge, H. C. – Nuttall, S. L. – Kendall, M. J.: Comparison of the β 1-selectivity of three β 1-selective β -blockers. *J Clin Pharm Ther*, 2003, 28, 17986.
- 8 Špinarová, I.: Nebivolol. *Farmakoterapie*, 2006, 2, s. 140–144.
- 9 Cleophas, T. J. – Grabowsky, I. – Menco, G., et al.: Long-term efficacy of nebivolol monotherapy in patients with hypertension. *Curr Ther Res*, 2001, 62, s. 451–461.
- 10 Nodari, S. – Mehra, M. – Dei Cas, L.: Betablocker treatment of patients with diastolic heart failure and arterial hypertension. A prospective, randomized comparison of the long-term effects of atenolol vs nebivolol. *Eur J Heart Failure*, 2003, 5, s. 621–627.
- 11 Kampus, P., et al.: Differential effects of nebivolol and metoprolol on central aortic pressure and left ventricular wall thickness. *Hypertension*, 2011, 57, s. 1122–1128.
- 12 Fogari, R., et al.: Comparative effects of nebivolol and atenolol on insulin sensitivity in hypertensive subjects with type II diabetes. *J Hum Hypertens*, 1997, 11, s. 753–757.
- 13 Flather, M. D. – Shibata, M. C. – Coats, A. J. S., et al.: Randomized trial to determine the effect of nebivolol on mortality and cardiovascular hospital admission in elderly patients with heart failure (SENIORS). *Eur Heart J*, 2005, 26, s. 215–225.

Fixní kombinovaná terapie rosuvastatinem a ezetimibem u pacienta s diabetem 2. typu a vysokým kardiovaskulárním rizikem

prof. MUDr. Hana Rosolová, DrSc. Centrum preventivní kardiologie, Univerzita Karlova, Lékařská fakulta v Plzni a 2. interní klinika Fakultní nemocnice Plzeň

- 1 Bohula, E. A. – Morrow, D. A. – Giugliano, R. P., et al.: Atherothrombotic risk stratification and ezetimibe for secondary prevention. *J Am Coll Cardiol*, 2017, 69, s. 911–921.
- 2 Hiramitsu, S. – Miyagishima, K. – Ishii, J., et al.: The effect of ezetimibe on lipid and glucose metabolism after a fat and glucose load. *J Cardiol*, 2012, 60, s. 395–400.
- 3 Varbo, A. – Benn, M. – Tybjaerg-Hansen, A., et al.: Remnant cholesterol as a causal risk factor for ischemic heart disease. *J Am Coll Cardiol*, 2013, 61, s. 427–436.

Včasné dosažení a dlouhodobé udržení optimálních hodnot krevního tlaku – fixní kombinační léčba v kazuistikách

MUDr. Milan Plíva Kardiologické centrum Agel, Interní klinika – kardiologické oddělení, Nemocnice Pardubického kraje, a. s.

- 1 WHO; World Heart Federation; World Stroke Organization: Global atlas on cardiovascular disease prevention and control. Policies, strategies and interventions. 2011, s. 164. Dostupné z: https://www.who.int/cardiovascular-diseases/publications/atlas_cvd/en/, vyhledáno 4. 12. 2020.
- 2 Cífková, R. – Bruthans, J. – Wohlfahrt, P., et al.: 30-year trends in blood pressure, prevalence, awareness, treatment and control of hypertension in the Czech republic. The chech MONICA and czech post-MONICA studies. *J Hypertens*, 2019, 37, s. e47.
- 3 Williams, B. – Mancia, G. – Spiering, W., et al.: 2018 ESC/ESH Guidelines for the management of arterial hypertension: The Task Force for the management of arterial hypertension of the European Society of Cardiology (ESC) and the European Society of Hypertension (ESH). *Eur Heart J*, 2018, 39, s. 3021–3023.
- 4 Wald, D. S. – Law, M. – Morris, J. K., et al.: Combination therapy versus monotherapy in reducing blood pressure: meta-analysis on 11,000 participants from 42 trials. *Am J Med*, 2009, 122, s. 290–300.
- 5 Rea, F. – Corrao, G. – Merlino, L., et al.: Early cardiovascular protection by initial two-drug fixed-dose combination treatment vs. monotherapy in hypertension. *Eur Heart J*, 2018, 39, s. 3654–3661.
- 6 Wanovich, R. – Kerrish, P. – Gerbino, P. P., et al.: P-518: Compliance patterns of patients treated with 2 separate antihypertensive agents versus fixed-dose combination therapy. *Am J Hypertens*, 2004, 17, s. 223A–223A.

7 Tóth, K., PIANIST Investigators: Antihypertensive efficacy of triple combination perindopril/indapamide plus amlodipine in high-risk hypertensives: results of the PIANIST study (Perindopril-Indapamide plus Amlodipine in high risk hypertensive patients). *Am J Cardiovasc*

Drugs, 2014, 14, s. 137–145.

8 Chalmers, J. – Arima, H. – Woodward, M., et al.: Effects of combination of perindopril, indapamide, and calcium channel blockers in patients with type 2 diabetes mellitus: results from the Action II

Diabetes and Vascular Disease: Preterax and Diamicon Controlled Evaluation (ADVANCE) trial. *Hypertension*, 2014, 63, s. 259–264.

Od glukocentrismu ke kardiorenální protektivě

prof. MUDr. Jan Škrha, DrSc. III. interní klinika – klinika endokrinologie a metabolismu 1. LF UK a VFN, Praha

1 The United Kingdom prospective diabetes study (UKPDS) group: Intensive blood glucose control with sulphonylurea or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). *Lancet*, 1998, 352, s. 837–853.

2 The Action to Control Cardiovascular Risk in Diabetes Study Group: Effects of intensive glucose lowering in type 2 diabetes. *N Engl J Med*, 2008, 358, s. 2545–2559.

3 Green, J. B. – Bethel, M. A. – Armstrong, P. W., et al.: Effect of sitagliptin on cardiovascular outcomes in type 2 diabetes. *N Engl J Med*, 2015, 373, s. 232–242.

4 Marso, S. P. – Daniels, G. H. – Brown-Frandsen, K., et al.: Liraglutide and cardiovascular outcomes in type 2 diabetes. *N Engl J Med*, 2016, 375, s. 311–322.

5 Zinman, B. – Wanner, C. – Lachin, J. M., et al.: Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. *N Engl J Med*, 2015, 373, s. 2117–2128.

6 Wiviott, S. D. – Raz, I. – Bonaca, M. P., et al.: DECLARE-TIMI 58 Investigators: Dapagliflozin and cardiovascular outcomes in type 2 diabetes. *N Engl J Med*, 2019, 380, s. 347–357.

7 ADA-EASD position statement on the management of hyperglycemia in type 2 diabetes: A patient centered approach (update). *Diabetologia*, 2015, 58, s. 429–442.

8 Gerstein, H. C. – Colhoun, H. M. – Dagenais, G. R., et al.; for the REWIND Investigators: Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind, randomised placebo-controlled trial. *Lancet*, 2019, 394, s. 121–130.

9 Heerspink, H. J. L. – Stefánsson, B. V. – Correa-Rotter, R., et al.; for the DAPA-CKD Trial Committees and Investigators: Dapagliflozin in patients with chronic kidney disease. *N Engl J Med*, 2020, 383, s. 1436–1446.

10 Scherthauer, G. – Shehadeh, N., et al.: World wide inertia to the use of cardiorenal protective glucose-lowering drugs (SGLT2i and GLP-1 RA) in high-risk patients with type 2 diabetes. *Cardiovascular Diabetology*, 2020, 19, 185, <https://doi.org/10.1186/s12933-020-01154-w>.

11 Sridhar, V. S. – Rahman, H. U. – Cherney, D. Z. I.: What have we learned about renal protection from the cardiovascular outcome trials and observational analyses with SGLT2 inhibitors? *Diabetes Obesity Metabolism*, 2020, 22, suppl. 1, s. 755–768.

Klinické zkušenosti s užitím inzulinu glargin 300 jednotek/ml v první linii u diabetes mellitus 2. typu

MUDr. Lucie Hoskovcová Interní klinika 2. LF UK a FN v Motole, Praha

1 Anderson, J. – Urquhart, S. – Spollett, G., et al.: Effective initiation and treatment with basal insulin in people with type 2 diabetes: focus on mitigating hypoglycemia in patients at increased risk. *Clinical Diabetes*, 2020, 38, s. 324–327.

2 Novodvorský, P.: Prínos inzulinu glargin 300 U/ml pre špecifické skupiny pacientov v kontexte dostupných dát. *Diabetes a obezita*,

2020, 20, s. 28–34.

3 Wexler, J. D.: Initial management of hyperglycemia in adults with type 2 diabetes mellitus. UpToDate, říjen 2020. Dostupné z: <https://www.uptodate.com/contents/initial-management-of-hyperglycemia-in-adults-with-type-2-diabetes-mellitus>, vyhledáno 19. 11. 2020.

4 Ritzel, R. – Roussel, R. – Bolli, G. B., et al.: Patient-level meta-analysis

of the EDITION 1, 2 and 3 studies: glycaemic control and hypoglycaemia with new insulin glargine 300 U/ml versus glargine 100 U/ml in people with type 2 diabetes. *Diabetes Obes Metab*, 2015, 17, s. 859–867.

Klinické zkušenosti s fixní kombinací inzulinu glargin a lixisenatidu

MUDr. Martina Tuháčková Interní klinika 2. LF UK a FN v Motole, Praha

1 Home, P. – Blonde, L. – Kalra, S., et al.: Insulin glargine/lixisenatide-fixed-ratio combination (iGlarLixi) compared with premix or addition of meal-time insulin to basal insulin in people with type 2 diabetes:

A systematic review and Bayesian network meta-analysis. *Diabetes Obes Metab*, 22. 7. 2020, doi: 10.1111/dom.14148.

2 Žák, P.: Úspěšné využití kombinace s fixním poměrem bazálního

inzulinu a GLP-1 RA u pacienta s téměř čtvrt století trvajícím diabetem 2. typu. *Kazuistiky v diabetologii*, 2019, 1, s. 10–12.

Bronchodilatační inhalační léčba u pacientů s CHOPN – aklidinium bromid v monoterapii, duální fixní kombinace aklidinium bromid / formoterol fumarát 2x denně

MUDr. Zuzana Perná Plicní ambulance, Medicon, a. s., Praha

1 Global Initiative for Chronic Obstructive Lung Disease. Global Strategy for the Diagnosis, Management and Prevention of Chronic Obstructive Pulmonary Disease: 2019. Dostupné z: <https://goldcopd.org/wp-content/uploads/2018/11/GOLD-2019v1.7-FINAL-14Nov2018-WMS.pdf>, vyhledáno 7. 2. 2019.

2 Bártů, V.: Nová duální kombinace aklidinium bromidu a formoterol fumarátu. *Remedia*, 2015, 6, s. 392–394.

3 Koblížek, V., et al.: Doporučený postup pro diagnostiku a léčbu stabilní CHOPN. ČPF5, 2013. Dostupné z: <https://chopn.registry.cz/res/file/publikace/doporučený-postup-diagnostika-lecba-chopn.pdf>,

vyhledáno 11. 9. 2020.

4 Wedzicha, J. A. – Agustí, A. – Donaldson, G., et al.: Effect of aclidinium bromide on exacerbations in patients with moderate-to-severe COPD: a pooled analysis of five phase III, randomized, placebo-controlled studies. *COPD*, 2016, 13, s. 669–676.

5 Wise, R. A. – Chapman, K. R. – Scirica, B. M., et al.: Long-term evaluation of the effects of aclidinium bromide on major adverse cardiovascular events and COPD exacerbations in patients with moderate to very severe COPD: rationale and design of the ASCENT COPD study. *Chronic Obstr Pulm Dis*, 2018, 5, s. 5–15.

6 Wise, R. A. – Chapman, K. R. – Scirica, B. M., et al.: Effect of aclidinium bromide on major cardiovascular events and exacerbation in high-risk patients with chronic obstructive pulmonary disease: The ASCENT-COPD randomized clinical trial. *JAMA*, 2019, 321, s. 1693–1701.

7 Bateman, E. D. – Chapman, K. R. – Singh, A., et al.: Aclidinium bromide and formoterol fumarate as a fixed-dose combination in COPD pooled analysis of symptoms and exacerbations from two six month multicentre, randomised studies (ACLIFORM and AUGMENT). *Respir Res*, 2015, 19, s. 1–11.

Biologická léčba napříč fenotypy těžkého astmatu

MUDr. Jana Klosová Oddělení alergologie a klinické imunologie, FN Ostrava

1 Kolbeck, R. – Kozhich, A. – Koike, M., et al.: MEDI-563, a humanized anti-IL-5 receptor alpha mAb with enhanced antibody-dependent cell-mediated cytotoxicity function. *J Allergy Clin Immunol*, 2010, 125, s. 1344–1353.

2 Lavolette, M. – Gossage, D. L. – Gauvreau, G., et al.: Effects of benralizumab on airway eosinophils in asthmatic patients with sputum eosinophilia. *J Allergy Clin Immunol*, 2013, 132, s. 1086–1096.

3 Tan, L. D. Bratt, J. M. – Godor, D., et al.: Benralizumab: a unique IL-5 inhibitor for severe asthma. *J Asthma Allergy*, 2016, 9, s. 71–81.

4 Licona-Limon, P. – Kim, L. K. – Palm, N.-W., et al.: TH2, allergy and group 2 innate lymphoid cells. *Nat Immunol*, 2013, 14, s. 536–542.

5 Lavolette, M. – Gossage, D. L. – Gauvreau, G., et al.: Effects of benralizumab on airway eosinophils in asthmatic patients with sputum eosinophilia. *J Allergy Clin Immunol*, 2013, 132, s. 1086–1096.e5.

6 Jackson, D. J. – Dube, S. – Morris, T., et al.: Real-world clinical outcomes for patients in the UK with severe, atopic eosinophilic asthma treated with benralizumab. Prezentováno na EAACI International Digital Congress, abstrakt 0698, 6.–8. 6. 2020, Londýn, UK.

7 FitzGerald, J. M. – Bleeker, E. R. – Menzies-Gow, A., et al.: Predictors of enhanced response with benralizumab for patients with severe asthma: pooled analysis of the SIROCCO and CALIMA studies. *Lancet Respir Med*, 2018, 6, s. 51–64.

8 Bleeker, E. R. – FitzGerald, J. M. – Chanez, P., et al.: Efficacy and safety of benralizumab for patients with severe asthma uncontrolled with high-dosage inhaled corticosteroids and long-acting β_2 -agonists (SIROCCO): a randomised, multicentre, placebo-controlled phase 3 trial. *Lancet*, 2016, 388, s. 2115–2127.

9 FitzGerald, J. M. – Bleeker, E. R. – Nair, P., et al.: Benralizumab, an anti-interleukin-5 receptor monoclonal antibody, as add-on treatment for patients with severe, uncontrolled, eosinophilic asthma (CALIMA): a randomised, double-blind, placebo-controlled phase 3 trial. *Lancet*, 2016, 388, s. 2128–2141.

10 Nair, P. – Wenzel, S. – Rabe, K. F., et al.: Oral glucocorticoid-sparing

- effect of benralizumab in severe asthma. *N Engl J Med*, 2017, 376, s. 2448–2458.
- 11 Busse, W. W. – Bleecker, E. R. – FitzGerald, J. M., et al.: Long-term safety and efficacy of benralizumab in patients with severe, uncontrolled asthma: 1-year results from the BORA phase 3 extension trial. *Lancet Respir Med*, 2019, 7, s. 46–59.
- 12 FitzGerald, J. M. – Bleecker, E. R. – Baurdin, A., et al.: Two-year integrated efficacy and safety analysis of benralizumab in severe asthma. *J Asthma Allergy*, 2019, 12, s. 401–413.
- 13 Bleecker, E. R. – Wechsler, M. E. – FitzGerald, J. M., et al.: Baseline patient factors impact on the clinical efficacy of benralizumab for severe asthma. *Eur Respir J*, 2018, 52, s. 1800936.
- 14 Jackson, D. J. – Humbert, M. – Hirsch, I., et al.: Ability of serum IgE concentration to predict exacerbation risk and benralizumab efficacy for patients with severe eosinophilic asthma. *Adv Ther*, 2020, 37, s. 718–729.

Astmatiký pacient u alergologa – adherence pacientů k léčbě zlepšuje léčebný efekt

MUDr. Iva Pončáková Centrum alergologie a klinické imunologie (CAKI) Nemocnice Na Homolce, Praha

- 1 Ohta, K. – Nagase H.: Adherence to asthma treatment. Global atlas of asthma, EAACI, 2013, s. 115–117. Dostupné z: https://www.allergique.org/IMG/Global_Atlas_of_Asthma.pdf, vyhledáno 21. 2. 2020.
- 2 Kašák, V. – Feketeová, E. – Špičák, V.: Analýza chybovosti v užívání inhalačních systémů v léčbě astmatu. *Alergie*, 2004, 6, suppl. 1, s. 42–48.
- 3 Craig, C., et al.: Dosing frequency and medication adherence in chronic disease. *J Manag Care Pharmacy*, 2012, 18, s. 527–539.
- 4 Diagnosis of diseases of chronic airflow limitation: Asthma, COPD and Asthma COPD Overlap Syndrome (ACOS). GINA 2014, GOLD 2014. Dostupné z: www.ginaasthma.org, vyhledáno 24. 5. 2019.
- 5 Global strategy for asthma management and prevention. Revised 2014. GINA 2014. Dostupné z: www.ginaasthma.org, vyhledáno 24. 5. 2019.
- 6 Global strategy for diagnosis, management and prevention of chronic obstructive pulmonary disease. GOLD Report, revised 2015. Dostupné z: www.goldcopd.org, vyhledáno 24. 5. 2019.
- 7 Koblížek, V. – Chlumský, J. – Zindr, V., et al.: *CHOPN. Doporučený postup ČPFS pro diagnostiku a léčbu chronické obstrukční plicní nemoci*. Praha, Maxdorf Jessenius, 2013.
- 8 Zdraví plic Evropy – fakta a čísla. ERS, ELF, 2013, ČARO, 2014.
- 9 Teř, M. – Čáp, P. – Dvořáková, R., et al.: *Doporučený postup diagnostiky a léčby bronchiálního astmatu*. ČPFS, ČSAKI, GEUM, 2015.
- 10 MacNee, W. – Rabinowich, R. – Choudhury, G.: Ageing and border between health and disease. *Eur Respir J*, 2014, 44, s. 1332–1352.
- 11 Allen, A. – Bareille, P. J. – Rousell, V. M.: Fluticasone furoate, a novel inhaled corticosteroid, demonstrated prolonged lung absorption kinetics in man compared with inhaled fluticasone propionate. *Clin Pharmacokinetics*, 2013, 52, s. 37–42.
- 12 Kašáková, E. – Kašák, V.: Inhalační systémy na českém trhu pro léčbu pacientů s chronickou obstrukcí průdušek. *Praktické lékařství*, 2015, 11, s. 16–18.

Inhalační kortikosteroidy v léčbě průduškového astmatu – principy léčby a význam výběru

doc. MUDr. Jaromír Bystron, CSc. Oddělení alergologie a klinické imunologie FN Ostrava (OAKI), JB Alergo-Imuno, s. r. o., Havířov

- 1 Global strategy for Asthma management and prevention – update 2020 (GINA 2020).

Atezolizumab ve druhé linii léčby nemalobuněčného plicního karcinomu

MUDr. Markéta Černovská Pneumologická klinika 1. LF UK a Thoamyerova nemocnice, Praha

- 1 McDermott, D. F. – Atkins, M. B.: PD-1 as a potential target in cancer therapy. *Cancer Medicine*, 2013, 2, s. 662–673.
- 2 Fehrenbacher, L. – Spira, A. – Ballinger, M., et al.: Atezolizumab versus docetaxel for patients with previously treated non-small cell lung cancer (POPLAR): a multicentre, open label, phase 2 randomised controlled trial. *Lancet*, 2016, 387, s. 1837–1846.
- 3 Rittmeyer, A. – Barlesi, F. – Waterkamp, D., et al.: Atezolizumab versus docetaxel in patients with previously treated non-small cell lung cancer (OAK): a phase 3, open label, multicentre randomised controlled trial. *Lancet*, 2017, 389, s. 255–265.
- 4 Shaorong, Y. – Delin, L. – Bo, S., et al.: Immunotherapy strategy of EGFR mutant lung cancer. *Am J Cancer Res*, 2018, 8, s. 2106–2115.
- 5 SPC Tecentriq (atezolizumab). European Medicines Agency, 2019. Dostupné z: <https://www.ema.europa.eu/en/medicines/human/epar/tecentriq>, vyhledáno 4. 12. 2020.
- 6 FDA Approves New Immunotherapy Drug for Bladder Cancer, National Cancer Institute, 7. 6. 2016, dostupné z: <https://www.cancer.gov/news-events/cancer-currents-blog/2016/fda-atezolizumab-bladder>, vyhledáno 4. 12. 2020.

Leiomyosarkom nadledviny léčený pazopanibem

MUDr. Hana Švébišová Onkologická klinika, LF UP a FN Olomouc

- 1 Viz <https://seer.cancer.gov>.
- 2 Mastrangelo, G. – Coindre, J. M. – Ducimetière, F., et al.: Incidence of soft tissue sarcoma and beyond: a population-based prospective study in 3 European regions. *Cancer*, 2012, 118, s. 5339–5348.
- 3 Stiller, C. A. – Trama, A. – Serraino, D., et al.: Descriptive epidemiology of sarcomas in Europe: report from the RARECARE project. *Eur J Cancer*, 2013, 49, s. 684–695.
- 4 Ferrari, A. – Sultan, I. – Huang, T. T., et al.: Soft tissue sarcoma across the age spectrum: a population-based study from the Surveillance Epidemiology and End Results database. *Pediatr Blood Cancer*, 2011, 57, s. 943–949.
- 5 Zagars, G. K. – Ballo, M. T. – Pisters, P. W., et al.: Prognostic factors for disease-specific survival after first relapse of soft-tissue sarcoma: analysis of 402 patients with disease relapse after initial conservative surgery and radiotherapy. *Int J Radiat Oncol Biol Phys*, 2003, 57, s. 739–747.
- 6 Kim, H. J. – Cho, Y. J. – Kim, S. H., et al.: Leiomyosarcoma: investigation of prognostic factors for risk-stratification model. *Int J Clin Oncol*, 2015, 20, s. 1226–1232.
- 7 Toto, J. R. – Travis, L. B. – Wu, H. J., et al.: Incidence patterns of soft tissue sarcomas, regardless of primary site, in the surveillance, epidemiology and end results program, 1978–2001: an analysis of 26,758 cases. *Int J Cancer*, 2006, 12, s. 2922–2930.
- 8 De Sanctis, R. – Marrari, A. – Marchetti, S., et al.: Efficacy of trabectedin in advanced soft tissue sarcoma: beyond lipo- and leiomyosarcoma. *Drug Des Devel Ther*, 2015, 9, s. 5785–5791.
- 9 Issels, R. D. – Schlemmer, M.: Current trials and new aspects in soft tissue sarcoma of adults. *Cancer Chemother Pharmacol*, 2002, 49, suppl. 1, s. S4–S8.
- 10 van Etten, B. – van Ijken, M. C. A. – Mooi, V. J., et al.: Primary leiomyosarcoma of the adrenal gland. *Sarcoma*, 2001, 5, s. 95–99.
- 11 Sakellariou, M. – Dellaportas, D. – Peppas, M., et al.: Review of the literature on leiomyoma and leiomyosarcoma of the adrenal gland: a systematic analysis of case reports. *In Vivo*, 2020, 34, s. 2233–2248.

Ninlaro – léčebná možnost relabujícího/refrakterního mnohočetného myelomu

MUDr. Viera Sandecká, Ph.D. Interní hematologická a onkologická klinika, FN Brno

- 1 Kyle, R. A. – Rajkumar, S. V.: Multiple myeloma. *Blood*, 2008, 111, s. 2962–2972.
- 2 Malúšková, D. – Svobodová, I. – Kučerová, M., et al.: Epidemiology of multiple myeloma in the Czech Republic. *Klin Onkol*, 2017, 30, s. 35–42.
- 3 Rajkumar, S. V.: Multiple myeloma: 2018 update on diagnosis, risk-stratification, and management. *Am J Hematol*, 2018, 93, s. 981–1114.
- 4 Moreau, P. – Richardson, P. G. – Cavo, M., et al.: Proteasome inhibitors in multiple myeloma: 10 years later. *Blood*, 2012, 120, s. 947–959.
- 5 Moreau, P. – Masszi, T. – Grzasko, N., et al.: Oral ixazomib, lenalidomide, and dexamethasone for multiple myeloma. *N Engl J Med*, 2016, 374, s. 1621–1634.
- 6 Richardson, P. G. – Baz, R. – Wang, M., et al.: Phase 1 study of twice-weekly ixazomib, an oral proteasome inhibitor, in relapsed/refractory multiple myeloma patients. *Blood*, 2014, 124, s. 1038–1046.
- 7 Kumar, S. K. – Bensinger, W. I. – Zimmermann, T. M., et al.: Phase 1 study of weekly dosing with the investigational oral proteasome inhibitor ixazomib in relapsed/refractory multiple myeloma. *Blood*, 2014, 124, s. 1047–1055.
- 8 Kumar, S. K. – Moreau, P. – Hari, P., et al.: Management of adverse events associated with ixazomib plus lenalidomide/dexamethasone in relapsed/refractory multiple myeloma. *Br J Haematol*, 2017.
- 9 Durie, B. G. – Salmon, S. E.: A clinical staging system for multiple myeloma. Correlation of measured myeloma cell mass with presenting clinical features, response to treatment, and survival. *Cancer*, 1975, 36, s. 842–854.
- 10 Greipp, P. R. – San Miguel, J. – Durie, B. G., et al.: International staging system for multiple myeloma. *J Clin Oncol*, 2005, 23, s. 3412–3420.
- 11 Palumbo, A. – Avet-Loiseau, H. – Oliva, S., et al.: Revised International Staging System for Multiple Myeloma: A Report From International Myeloma Working Group. *J Clin Oncol*, 2015, 33, s. 2863–2869.
- 12 Moreau, P. – Dimopoulos, M. A. – Yong, K., et al.: Isatuximab plus carfilzomib/dexamethasone versus carfilzomib/dexamethasone in patients with relapsed/refractory multiple myeloma: IKEMA Phase III study design. *Future Oncol*, 2020, 16, s. 4347–4358.

Léčba epizodické nenádorové bolesti kombinací tramadolu a paracetamolu

MUDr. Marek Pieran Ambulance pro léčbu chronické bolesti při Klinice anestezie a resuscitace FN Olomouc

- 1 Högestätt, E. D., et al.: Conversion of acetaminophen to the bioactive N-acetylphenolamine AM404 via fatty acid amide hydrolase-dependent arachidonic acid conjugation in the nervous system. *J Biol Chemistry*, 2005, 280, s. 31405–31412.
- 2 Mallet, Ch., et al.: TRPV1 in brain is involved in acetaminophen-induced antinociception. *PLoS one*, 2010, 5, s. 9.
- 3 Kršák, M.: Jak zvýšit analgetickou účinnost paracetamolu? *Inter Med*, 2011, 13, s. 140–142.
- 4 Pergolizzi, J. R., et al.: Tramadol/paracetamol fixed-dose combination in the treatment of moderate to severe pain. *J Pain Res*, 2012, 5, s. 327.
- 5 Doseděl, M.: Nežádoucí účinky a lékové interakce nesteroidních antiflogistik a jejich management pohledem farmaceuta. *Praktické lékárenství*, 2014, 10, s. 90–94.
- 6 Prokeš, M. – Suchopár, J.: Kombinovaná analgetika-antipyretika a jejich rizika. *Med Praxi*, 2015, 12, s. 247–251.

Využití eribulinu v léčbě karcinomu prsu u starších žen

MUDr. Zuzana Donátová | MUDr. Drahomíra Kordíková Onkologická klinika 1. LF UK a Thomayerova nemocnice, Praha

- 1 Ferlay, J. – Soerjomataram, I. – Dikshit, R., et al.: Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. *Int J Cancer*, 2015, 136, s. E359–E386.
- 2 Cardoso, F. – Costa, A. – Senkus, E., et al.: 3rd ESO-ESMO international consensus guidelines for advanced breast cancer (ABC 3). *Ann Oncol*, 2017, 28, s. 16–33.
- 3 Cortes, J. – O’Shaughnessy, J. – Loesch, D., et al.: Eribulin monotherapy versus treatment of physician’s choice in patients with metastatic breast cancer (EMBRACE): a phase 3 open-label randomised study. *Lancet*, 2011, 377, s. 914–923.
- 4 Kaufman, P. A. – Awada, A. – Twelves, C., et al.: Phase III open label randomized study of eribulin mesylate versus capecitabine in patients with locally advanced or metastatic breast cancer previously treated with an anthracycline and a taxane. *J Clin Oncol*, 2015, 33, s. 594–601.
- 5 Twelves, C. – Awada, A. – Cortes, J., et al.: Subgroup analyses from a phase 3, open-label, randomized study of eribulin mesylate versus capecitabine in pretreated patients with advanced or metastatic breast cancer. *Breast Cancer Basic Clin Res*, 2016, 10, s. 77–84.
- 6 Barni, S. – Livraghi, L. – Morrilli, M., et al.: Eribulin in the treatment of advanced breast cancer: real-world scenario from 39 Italian centers – ESEMPIO study. *Future Oncol*, 2019, 15, s. 33–44.
- 7 Dell’Ova, M. – De Maio, E. – Guiu, S., et al.: Tumour biology, metastatic sites and taxanes sensitivity as determinants of eribulin mesylate efficacy in breast cancer: results from the ERIBEX retrospective, international, multicentre study. *BMC Cancer*, 2015, 15, s. 659.
- 8 Aftimos, P. – Polastro, L. – Ameye, L., et al.: Results of the Belgian expanded access program of eribulin in the treatment of metastatic breast cancer closely mirror those of the pivotal phase III trial. *Eur J Cancer*, 2016, 60, s. 117–124.
- 9 Jacot, W. – Heudel, P.-E. – Fraisse, J., et al.: Real-life activity of eribulin mesylate among metastatic breast cancer patients in the multicenter national observational ESME program. *Int J Cancer*, 2019, 145, s. 3359–3369.
- 10 Orditura, M. – Gravina, A. – Riccardi, F., et al.: Eribulin for metastatic breast cancer (MBC) treatment: a retrospective, multicenter study based in Campania, South Italy (Eri-001 trial). *ESMO Open*, 2017, 2, e000176, doi: 10.1136/esmoopen-2017-000176. eCollection 2017.
- 11 Martin-Babau, J. – Robert, M. – Seegers, V., et al.: Eribulin is safe and efficient in metastatic breast cancer in elderly patients. Results from the REPROLINE multicentric retro-prospective cohort. *Ann Oncol*, 2017, 28, 10.1093/annonc/mdx365.062.
- 12 Pedersini, R. – di Mauro, P. – Amoroso, V., et al.: Efficacy of eribulin mesylate in older patients with breast cancer: A pooled analysis of clinical trial and real-world data. *J Geriatr Oncol*, 2020, 11, s. 976–981.
- 13 Muss, H. – Cortes, J. – Vahdat, L. T., et al.: Eribulin monotherapy in patients aged 70 years and older with metastatic breast cancer. *Oncologist*, 2014, 19, s. 318–327.
- 14 Leo, S. – Arnoldi, E. – Repetto, L., et al.: Eribulin mesylate as third or subsequent line chemotherapy for elderly patients with locally recurrent or metastatic breast cancer: a multicentric observational study of GIOGer (Italian Group of Geriatric Oncology) – ERIBE. *Oncologist*, 2019, 24, s. e232–e240.
- 15 de Nonneville, A. – Sabatier, R. – Gonçalves, A., et al.: Safety and efficacy of eribulin for “real-world” older patients with metastatic breast cancer. *J Geriatr Oncol*, 2018, 9, s. 281–283.
- 16 Pedersini, R. – Vassalli, L. – Claps, M., et al.: Eribulin in heavily pretreated metastatic breast cancer patients in the real world: a retrospective study. *Oncology*, 2018, 94, suppl. 1, s. 10–15.
- 17 Barni, S. – Livraghi, L. – Gravina, A., et al.: Feasibility of eribulin mesylate in older patients with locally advanced or metastatic breast cancer: a post-hoc analysis of the ESEMPIO study. *J Geriatr Oncol*, 2019, 10, s. 990–993.

Nepeglyovaný lipozomální doxorubicin v léčbě metastatického hormonálně dependentního nádoru prsu

MUDr. Dagmar Brančíková, Ph.D. Interní hematologická a onkologická klinika FN Brno

- 1 Cardoso, F., et al.: ESO-ESMO International Consensus Guidelines for Advanced Breast Cancer – ABC. *Ann Oncol*, 2020, 31, 12.
- 2 Rosas, D. – Raez, L. E.: Review of the agnostic-type treatment approach: treating cancer by mutations, not by location. *Oncol Ther*, 2020, 8, s. 59–66.
- 3 Martos-Benítez, F. D. – Soler-Morejón, C. D. – Lara-Ponce, K. X., et al.: Critically ill patients with cancer: A clinical perspective. *World J Clin Oncol*, 2020, 11, s. 809–835.
- 4 Mamouch, F. – Berrada, N. – Aoullay, Z., et al.: Inflammatory breast cancer: a literature review. *World J Oncol*, 2018, 9, s. 129–135.
- 5 Diao, J. D. – Ma, L. X. – Sun, M. Y., et al.: Construction and validation of a nomogram to predict overall survival in patients with inflammatory breast cancer. *Cancer Med*, 2019, 8, s. 5600–5608.
- 6 Masuda, H. – Brewer, T. M. – Liu, D. D., et al.: Long-term treatment efficacy in primary inflammatory breast cancer by hormonal receptor- and HER2-defined subtypes. *Ann Oncol*, 2014, 25, s. 384–391.

Lipidový komplex amfotericinu B a jeho místo vedle moderních antimykotik

MUDr. Peter Múdry, Ph.D. Klinika dětské onkologie LF MU a FN Brno

- 1 Steimbach, L. M. – Tonin, F. S. – Virtuoso, S., et al.: Efficacy and safety of amphotericin B lipid-based formulations-A systematic review and meta-analysis. *Mycoses*, 2017, 60, s. 146–154.
- 2 Sterba, J. – Prochazka, J. – Ventruha, J., et al.: Successful treatment of aspergillus brain abscess in a child with acute lymphoblastic leukemia and liver failure. *Pediatr Hematol Oncol*, 2005, 22, s. 649–655.
- 3 Cecinati, V. – Guastadisegni, Ch. – Giovanni Russo, F., et al.: Antifungal therapy in children: an update. *Eur J Pediatr*, 2013, 172, s. 437–446.
- 4 Chen, L. – Wang, Y. – Zhang, T., et al.: Utility of posaconazole therapeutic drug monitoring and assessment of plasma concentration threshold for effective prophylaxis of invasive fungal infections: a meta-analysis with trial sequential analysis. *BMC Infect Dis*, 2018, 18, s. 155.
- 5 Schauwvlieghe, A. F. A. D. – Buil, J. B. – Verweij, P. E., et al.: High-dose posaconazole for azole-resistant aspergillosis and other difficult-to-treat mould infections. *Mycoses*, 2020, 63, s. 122–130.

Režim ATRA+ATO u pacientů s nízkým a středním rizikem akutnej promyelocytové leukémie – sledovanie hepatálnej toxicity a hyperleukocytózy

MUDr. Iveta Oravcová, PhD. | MUDr. Eva Mikušková, PhD. | MUDr. Ľudmila Demitrovičová, PhD. | MUDr. Vanda Mikudová |

MUDr. Silvia Cingelová, PhD. | MUDr. Alica Slobodová | MUDr. Jana Jankechová Oddelenie onkohematológie II, Klinika

onkohematológie LF UK a NOÚ, Bratislava

doc. MUDr. Ľuboš Drgoňa, CSc. Oddelenie onkohematológie I a II, Klinika onkohematológie LFUK a NOÚ, Bratislava

- 1 Sanz, M. A. – Fenaux, P. – Tallman, M. S., et al.: Management of acute promyelocytic leukemia: updated recommendations from an expert panel of the European Leukemia Net. *Blood*, 2019, 133, s. 1630–1643.
- 2 Cicconi, L. – Lo Coco, F.: Current management of acute promyelocytic leukemia. *An Oncol*, 2016, 27, s. 1474–1481.
- 3 Abedin, S. – Altman, J. K.: Acute promyelocytic leukemia: preventing early complications and late toxicities. *ASH Education Book 2016. Hematology*, 2016, s. 10–15.
- 4 Mathews, V. – Desire, S. – George, B., et al.: Hepatotoxicity profile of single agent arsenic trioxide in the treatment of newly diagnosed acute promyelocytic leukemia, its impact on clinical outcome and the effect of genetic polymorphisms on the incidence of hepatotoxicity. *Leukemia*, 2006, 20, s. 881–883.
- 5 Mathews, V. – George, B. – Lakshmi, K. M., et al.: Single-agent arsenic trioxide in the treatment of newly diagnosed acute promyelocytic leukemia: durable remissions with minimal toxicity. *Blood*, 2006, 107, s. 2627–2632.
- 6 Lo-Coco, F. – Avvisati, G. – Vignetti, M., et al.: for Gruppo Italiano Malattie Ematologiche dell’Adulto, the German-Austrian Acute Myeloid Leukemia Study Group, and Study Alliance Leukemia: Retinoic acid and arsenic trioxide for acute promyelocytic leukemia. *N Engl J Med*, 2013, 369, s. 111–121.
- 7 Long, Z. J. – Hu, Y. – Li, X. D., et al.: ATO/ATRA/anthracycline-chemotherapy sequential consolidation achieves long-term efficacy in primary acute promyelocytic leukemia. *PLoS One*, 2014, 9, s. 1–8, e104610.
- 8 Platzbecker, U. – Avvisati, A. – Cicconi, L., et al.: Improved outcomes with retinoic acid and arsenic trioxide compared with retinoic acid and chemotherapy in non-high-risk acute promyelocytic leukemia: final results of the randomized Italian-German APL0406 Trial. *J Clin Oncol*, 2017, 35, s. 605–612.

Leukocytóza a diferenciační syndrom při léčbě akutní promyelocytární leukemie pomocí oxidu arsenitého

MUDr. Zdeněk Kořístek, Ph.D. Klinika hematologie, Fakultní nemocnice Ostrava

- 1 Sanz, M. A. – LoCoco, F. – Martín, G., et al.: Definition of relapse risk and role of non-anthracycline drugs for consolidation in patients with acute promyelocytic leukemia: a joint study of the PETHEMA and GEMEMA cooperative groups. *Blood*, 2000, 96, s. 1247–1253.
- 2 LoCoco, F. – Avvisati, G. – Vignetti, M., et al.: Retinoic acid and arsenic trioxide for acute promyelocytic leukemia. *N Engl J Med*, 2013, 369, s. 111–121.
- 3 Sanz, M. A. – Montesinos, P. – Rayón, C., et al.: Risk-adapted treatment of acute promyelocytic leukemia based on all-trans retinoic acid and anthracycline with addition of cytarabine in consolidation therapy for high-risk patients: further improvements in treatment outcome. *Blood*, 2010, 115, s. 5137–5146.
- 4 Cicconi, L. – Platzbecker, U. – Avvisati, G., et al.: Long-term results of all-trans retinoic acid and arsenic trioxide in non-high-risk acute promyelocytic leukemia: update of the APL0406 Italian-German randomized trial. *Leukemia*, 2020, 34, s. 914–918.
- 5 Camacho, L. H. – Soignet, S. L. – Chanel, S., et al.: Leukocytosis and the retinoic acid syndrome in patients with acute promyelocytic leukemia treated with arsenic trioxide. *J Clin Oncol*, 2000, 18, s. 2620–2625.
- 6 Mathews, V. – George, B. – Chendamalai, E.: Single-agent arsenic trioxide in the treatment of newly diagnosed acute promyelocytic leukemia: long-term follow-up data. *J Clin Oncol*, 2010, 28, s. 3866–3871.
- 7 Platzbecker, U. – Avvisati, G. – Cicconi, L., et al.: Improved outcomes with retinoic acid and arsenic trioxide compared with retinoic acid and chemotherapy in non-high-risk acute promyelocytic leukemia: final results of the randomized Italian-German APL0406 trial. *J Clin Oncol*, 2017, 35, s. 605–612.

Získaná hemofilie A: možnosti diagnostiky a léčby

MUDr. Jaromír Gumulec | MUDr. Zdeněk Kořístek, Ph.D. | MUDr. Milan Navrátil | MUDr. David Buffa | MUDr. Katarína Hradská

Klinika hematologie FN Ostrava a LF Ostravské univerzity

MUDr. Lucie Recová Oddělení klinické hematologie Ústavu laboratorní diagnostiky FN Ostrava a LF Ostravské univerzity

MUDr. Radomíra Hrdličková Krevní centrum FN Ostrava a LF Ostravské univerzity

MUDr. Martin Pulcer, Ph.D. Oddělení klinické hematologie Ústavu laboratorní diagnostiky FN Ostrava a LF Ostravské univerzity

doc. MUDr. Zuzana Čermáková, Ph.D. Krevní centrum FN Ostrava a LF Ostravské univerzity

prof. MUDr. Roman Hájek, CSc. Klinika hematologie FN Ostrava a LF Ostravské univerzity

- 1 Knoebel, P., et al.: Demographic and clinical data in acquired hemophilia A: results from the European Acquired Haemophilia Registry (EACH2). *J Thromb Haemost*, 2012, 10, s. 622–631.
- 2 Borg, J. Y., et al.: Outcome of acquired hemophilia in France: the prospective SACHA (Surveillance des Auto antiCorps au cours de l'Hemophilie Acquisée) registry. *Haemophilia*, 2013, 19, s. 564–570.
- 3 Collins, P. W., et al.: Diagnosis and management of acquired coagulation inhibitors: a guideline from UKHCDO. *Br J Haematol*, 2013, 162, s. 758–773.
- 4 Knobl, P.: Prevention and management of bleeding episodes in patients with acquired hemophilia A. *Drugs*, 2018, 78, s. 1861–1872.
- 5 Baudo, F., et al.: Management of bleeding in acquired hemophilia A: results from the European Acquired Haemophilia (EACH2) Registry. *Blood*, 2012, 120, s. 39–46.
- 6 Green, D. – Lechner, K.: A survey of 215 non-hemophilic patients with inhibitors to Factor VIII. *Thromb Haemost*, 1981, 45, s. 200–203.
- 7 Kruse-Jarres, R., et al.: Acquired hemophilia A: Updated review of evidence and treatment guidance. *Am J Hematol*, 2017, 92, s. 695–705.
- 8 Tiede, A., et al.: Prognostic factors for remission of and survival in acquired hemophilia A (AHA): results from the GTH-AH 01/2010 study. *Blood*, 2015, 125, s. 1091–1097.
- 9 Tiede, A., et al.: Anti-factor VIII IgA as a potential marker of poor prognosis in acquired hemophilia A: results from the GTH-AH 01/2010 study. *Blood*, 2016, 127, s. 2289–2289.
- 10 Hofbauer, C. J., et al.: Affinity of FVIII-specific antibodies reveals major differences between neutralizing and nonneutralizing antibodies in humans. *Blood*, 2015, 125, s. 1180–1188.
- 11 Werwitzke, S., et al.: Diagnostic and prognostic value of factor VIII binding antibodies in acquired hemophilia A: data from the GTH-AH 01/2010 study. *J Thromb Haemost*, 2016, 14, s. 940–947.
- 12 Federici, A. B., et al.: Current diagnostic and therapeutic approaches to patients with acquired von Willebrand syndrome: a 2013 update. *Semin Thromb Hemost*, 2013, 39, s. 191–201.
- 13 Tiede, A. – Werwitzke, S. – Scharf, R. E.: Laboratory diagnosis of acquired hemophilia A: Limitations, consequences, and challenges. *Semin Thromb Hemost*, 2014, 40, s. 803–811.
- 14 Verbruggen, B., et al.: The Nijmegen modification of the Bethesda assay for factor VIII:C inhibitors: improved specificity and reliability. *Thromb Haemost*, 1995, 73, s. 247–251.
- 15 Toschi, V. – Baudo, F.: Diagnosis, laboratory aspects and management of acquired hemophilia A. *Intern Emerg Med*, 2010, 5, s. 325–333.
- 16 Collins, P. W. – Percy, C. L.: Advances in the understanding of acquired hemophilia A: implications for clinical practice. *Br J Haematol*, 2010, 148, s. 183–194.
- 17 Kessler, C. M. – Knobl, P.: Acquired hemophilia: an overview for clinical practice. *Eur J Haematol*, 2015, 95, suppl. 81, s. 36–44.
- 18 Collins, P., et al.: Epidemiology and general guidelines of the management of acquired hemophilia and von Willebrand syndrome. *Haemophilia*, 2008, 14, suppl. 3, s. 49–55.
- 19 Sallah, S.: Treatment of acquired hemophilia with factor eight inhibitor bypassing activity. *Haemophilia*, 2004, 10, s. 169–173.
- 20 Collins, P., et al.: Consensus recommendations for the diagnosis and treatment of acquired hemophilia A. *BMC Res Notes*, 2010, 3, s. 161.
- 21 Huth-Kuhne, A., et al.: International recommendations on the diagnosis and treatment of patients with acquired hemophilia A. *Haematologica*, 2009, 94, s. 566–575.
- 22 Srivastava, A., et al.: Guidelines for the management of hemophilia. *Haemophilia*, 2013, 19, s. e1–e47.
- 23 Nemes, L. – Pitlik, E.: New protocol for immune tolerance induction in acquired hemophilia. *Haematologica*, 2000, 85, suppl. 10, s. 64–68.
- 24 Ehrlich, H. J. – Henzl, M. J. – Gomperts, E. D.: Safety of factor VIII inhibitor bypass activity (FEIBA): 10-year compilation of thrombotic adverse events. *Haemophilia*, 2002, 8, s. 83–90.
- 25 Collins, P., et al.: Immunosuppression for acquired hemophilia A: results from the European Acquired Haemophilia Registry (EACH2). *Blood*, 2012, 120, s. 47–55.
- 26 Tengborn, L., et al.: Pregnancy-associated acquired hemophilia A: results from the European Acquired Haemophilia (EACH2) registry. *BJOG*, 2012, 119, s. 1529–1537.
- 27 Kessler, C. M., et al.: Assessment of acquired hemophilia patient demographics in the United States: the Hemostasis and Thrombosis Research Society Registry. *Blood Coagul Fibrinolysis*, 2016, 27, s. 761–769.
- 28 Green, D. – Rademaker, A. W. – Briet, E.: A prospective, randomized trial of prednisone and cyclophosphamide in the treatment of patients with factor VIII autoantibodies. *Thromb Haemost*, 1993, 70, s. 753–757.
- 29 Franchini, M. – Mannucci, P. M.: Inhibitor eradication with rituximab in hemophilia: where do we stand? *Br J Haematol*, 2014, 165, s. 600–608.
- 30 Zeng, Y., et al.: Rituximab for eradicating inhibitors in people with acquired hemophilia A. *Cochrane Database Syst Rev*, 2016, 7, s. CD011907.
- 31 Tiede, A., et al.: Management of acquired hemophilia A. *Haemostaseologie*, 2015, 35, s. 311–318.
- 32 Napolitano, M., et al.: Acquired hemophilia in cancer: A systematic and critical literature review. *Haemophilia*, 2018, 24, s. 43–56.
- 33 Kreuter, M., et al.: Acquired hemophilia in a patient with gram-negative urosepsis and bladder cancer. *Haemophilia*, 2005, 11, s. 181–185.

Pestrost lidských povah je příčinou, proč někdy vážně komunikace mezi pacientem a lékařem

PhDr. Mgr. Jeroným Klimeš, Ph.D. Soukromá psychologická ambulance, Praha

doc. MUDr. Zdeněk Boleloucký, CSc. Psychiatrická klinika LF MU a FN Brno

prof. MUDr. Zdeněk Adam, CSc. Interní hematologická a onkologická klinika LF MU a FN Brno

MUDr. Zuzana Adamová, Ph.D. Chirurgické oddělení, Vsetínská Nemocnice, a. s.

- 1 Adam, Z. – Klimeš, J. – Pour, L., et al.: *Maligní onemocnění, psychika a stres*. Praha, Grada Publishing, 2019.
- 2 Balon, R.: *Poruchy osobnosti*. Psychiatrie, Praha, Tigis, 2004, s. 540–556.
- 3 Berne, E.: *Jak si lidé hrají*. Praha, Portál, 2011.
- 4 Boleloucký, Z., et al.: *Hraniční stavy v psychiatrii*. Praha, Avicenum, Grada, 1993.
- 5 Dragomirecká, E. – Baudiš, P. – Smolová, E., et al.: Psychiatrická nemocnost obyvatel České republiky. *Čes Slov Psychiat*, 2002, 2, s. 72–80.
- 6 Honzák R.: Jak se bránit duševním upírům. *Lékařské listy*, 2013, 3, s. 41–42.
- 7 Höschl, C. – Švestka, J. – Libier, J.: *Psychiatrie*. Praha, Tigis, 2002.
- 8 Klimeš, J.: *Partneři a rozchody*. Portál, Praha, 2005.
- 9 Klimeš, J.: *Nemoc a naše psychika*. Praha, Lymfom help, 2013. Dostupné z: <http://nemocapsychika.klimes.us>, vyhledáno 31. 8. 2020.
- 10 Langmeier, J. – Matějček, Z.: *Psychická deprivace v dětství*. Praha, Nakladatelství Karolinum, 2014.
- 11 Lensing, M. B. – Zeiner, P. – Sandvik, L., et al.: Quality of life in adults aged 50+ with ADHD. *J Atten Disord*, 2015, 19, s. 405–413.
- 12 Nazare-Aga, I.: *Láska a manipulace*. Praha, Portál, 2003.
- 13 Nazare-Aga, I.: *Nenechte sebou manipulovat*. Praha, Portál, 2014.
- 14 Praško, J.: *Poruchy osobnosti*. Praha, Portál, 2003.
- 15 Praško, J.: *Poruchy osobnosti*. Praha, Portál, 2009.